Silvia Soddu

List of Publications by Year
in descending order

121 papers	5,539 citations	57758 44 h-index	88630 70 g-index
126 all docs	126 docs citations	126 times ranked	6591 citing authors

#	Article	IF	Citations
1	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. Molecular Cancer Research, 2022, 20, 686-698.	3.4	5
2	Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties. Cell Death and Disease, 2021, 12, 558.	6.3	7
3	Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene. Life Science Alliance, 2021, 4, e202101019.	2.8	2
4	Functional Classification of the ATM Variant c.7157C>A and In Vitro Effects of Dexamethasone. Frontiers in Genetics, 2021, 12, 759467.	2.3	0
5	TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability. Cancer Letters, 2020, 473, 98-106.	7.2	16
6	HIPK2 Is Required for Midbody Remnant Removal Through Autophagy-Mediated Degradation. Frontiers in Cell and Developmental Biology, 2020, 8, 572094.	3.7	7
7	Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. Journal of Experimental and Clinical Cancer Research, 2020, 39, 46.	8.6	108
8	HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53â€dependent mitochondrial apoptosis. EMBO Reports, 2020, 21, e48073.	4.5	23
9	An Alternative Splice Variant of HIPK2 with Intron Retention Contributes to Cytokinesis. Cells, 2020, 9, 484.	4.1	13
10	The Cockayne syndrome group A and B proteins are part of a ubiquitinâ€"proteasome degradation complex regulating cell division. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30498-30508.	7.1	15
11	Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. Life Science Alliance, 2020, 3, e202000799.	2.8	19
12	HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer. Oncology Reports, 2020, 45, 899-910.	2.6	2
13	HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission. Cells, 2019, 8, 684.	4.1	31
14	p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway. Cell Death and Disease, 2019, 10, 850.	6.3	26
15	Extrachromosomal Histone H2B Contributes to the Formation of the Abscission Site for Cell Division. Cells, 2019, 8, 1391.	4.1	4
16	Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. Journal of Experimental and Clinical Cancer Research, 2019, 38, 108.	8.6	34
17	HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis. Oncogene, 2018, 37, 3562-3574.	5.9	15
18	Mice with reduced expression of the telomereâ€associated protein Ft1 develop p53â€sensitive progeroid traits. Aging Cell, 2018, 17, e12730.	6.7	24

#	Article	IF	Citations
19	Effects of Y361â€autoâ€phosphorylation on structural plasticity of the HIPK2 kinase domain. Protein Science, 2018, 27, 725-737.	7.6	4
20	MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death and Disease, 2018, 9, 895.	6.3	35
21	CDKL5 localizes at the centrosome and midbody and is required for faithful cell division. Scientific Reports, 2017, 7, 6228.	3.3	27
22	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 2017, 8, 108463-108479.	1.8	8
23	HIPK2-T566 autophosphorylation diversely contributes to UV- and doxorubicin-induced HIPK2 activation. Oncotarget, 2017, 8, 16744-16754.	1.8	6
24	Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2-Î”e8 isoform. Oncotarget, 2016, 7, 1675-1686.	1.8	5
25	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 135.	8.6	9
26	Epitelial-to-mesenchimal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells. Journal of Experimental and Clinical Cancer Research, 2016, 35, 24.	8.6	33
27	MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene, 2016, 35, 228-240.	5.9	33
28	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene, 2016, 35, 887-896.	5.9	13
29	Prognostic role of serum p53 antibodies in lung cancer. BMC Cancer, 2015, 15, 148.	2.6	32
30	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Oncogene, 2015, 34, 2493-2504.	5.9	59
31	Abstract 4316: hMENA11acontributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1
32	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget, 2015, 6, 10320-10334.	1.8	30
33	Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status. International Journal of Radiation Biology, 2014, 90, 248-255.	1.8	53
34	HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation. Cell Death and Disease, 2014, 5, e1414-e1414.	6.3	11
35	Mutant cohesin drives chromosomal instability in early colorectal adenomas. Human Molecular Genetics, 2014, 23, 6773-6778.	2.9	30
36	Serum p53 antibody detection in patients with impaired lung function. BMC Cancer, 2013, 13, 62.	2.6	10

#	Article	IF	Citations
37	ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. Journal of Experimental and Clinical Cancer Research, 2013, 32, 95.	8.6	81
38	HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1443-1453.	4.1	47
39	Pax8 has a critical role in epithelial cell survival and proliferation. Cell Death and Disease, 2013, 4, e729-e729.	6.3	50
40	p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes. Journal of Clinical Investigation, 2013, 123, 1335-1342.	8.2	20
41	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2013, 123, 4979-4979.	8.2	0
42	467 HIPK2 in the Control of Chromosomal Instability â€" a New Mechanism in Tumorigenesis. European Journal of Cancer, 2012, 48, S112.	2.8	0
43	HIPK2 Controls Cytokinesis and Prevents Tetraploidization by Phosphorylating Histone H2B at the Midbody. Molecular Cell, 2012, 47, 87-98.	9.7	58
44	Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 63.	8.6	81
45	PKC Theta Ablation Improves Healing in a Mouse Model of Muscular Dystrophy. PLoS ONE, 2012, 7, e31515.	2.5	39
46	HIPK2 phosphorylates Î"Np63Î± and promotes its degradation in response to DNA damage. Oncogene, 2011, 30, 4802-4813.	5.9	57
47	Homeodomain-interacting Protein Kinase-2 Stabilizes p27kip1 by Its Phosphorylation at Serine 10 and Contributes to Cell Motility. Journal of Biological Chemistry, 2011, 286, 29005-29013.	3.4	9
48	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. Molecular Cancer Research, 2011, 9, 67-77.	3.4	30
49	The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas. PLoS ONE, 2011, 6, e20665.	2.5	54
50	In-vitro and in-vivo detection of p53 by fluorescence lifetime on a hybrid FITC-gold nanosensor. , 2010, , .		2
51	Abstract P3-06-01: ATM Heterozygosity as a Breast Cancer-Susceptibility Factor in the General Population. , 2010, , .		0
52	Homeodomain Interacting Protein Kinase 2 Activation Compromises Endothelial Cell Response to Laminar Flow: Protective Role of p21waf1,cip1,sdi1. PLoS ONE, 2009, 4, e6603.	2.5	8
53	Negative Regulation of Î²4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. Cancer Research, 2009, 69, 5978-5986.	0.9	48
54	Targeted Disruption of the Murine Homeodomain-Interacting Protein Kinase-2 Causes Growth Deficiency In Vivo and Cell Cycle Arrest In Vitro. DNA and Cell Biology, 2009, 28, 161-167.	1.9	20

#	Article	IF	Citations
55	p53 Detection by Fluorescence Lifetime on a Hybrid Fluorescein Isothiocyanate Gold Nanosensor. Journal of Biomedical Nanotechnology, 2009, 5, 683-691.	1.1	12
56	HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA. Cancer Research, 2009, 69, 6241-6248.	0.9	49
57	Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. Journal of Molecular Medicine, 2009, 87, 1221-1239.	3.9	88
58	<i>Galâ€3</i> is stimulated by gainâ€ofâ€function <i>p53</i> mutations and modulates chemoresistance in anaplastic thyroid carcinomas. Journal of Pathology, 2009, 218, 66-75.	4.5	33
59	HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Proliferation, 2009, 42, 373-384.	5.3	33
60	MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO Journal, 2009, 28, 1926-1939.	7.8	75
61	Methylâ€CpGâ€binding protein 2 is phosphorylated by homeodomainâ€interacting protein kinase 2 and contributes to apoptosis. EMBO Reports, 2009, 10, 1327-1333.	4.5	63
62	HIPKs: Jack of all trades in basic nuclear activities. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2124-2129.	4.1	58
63	MDM2-Regulated Degradation of HIPK2 Prevents p53Ser46 Phosphorylation and DNA Damage-Induced Apoptosis. Molecular Cell, 2007, 25, 739-750.	9.7	161
64	Investigation into the reactivity of the coordinatively unsaturated phosphonodithioato [Ni(MeOpdt)2] towards 2,4,6-tris(2-pyridyl)-1,3,5-triazine: goals and achievements. Dalton Transactions, 2007, , 2127.	3.3	20
65	HIPK2: a multitalented partner for transcription factors in DNA damage response and developmentThis paper is one of a selection of papers published in this Special Issue, entitled 28th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology, 2007, 85, 411-418.	2.0	115
66	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2007, 117, 693-702.	8.2	88
67	Analysis ofÂtheÂrole ofÂp53 andÂGalectin-3 inÂproliferation andÂapoptosis ofÂthyroid carcinoma cell lines byÂspecific RNA interference experiments. Biomedicine and Pharmacotherapy, 2006, 60, 491.	5.6	0
68	Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Letters, 2006, 231, 102-112.	7.2	17
69	High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death and Differentiation, 2006, 13, 1554-1563.	11.2	65
70	Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death and Differentiation, 2006, 13, 1994-1997.	11.2	32
71	câ€Abl acetylation by histone acetyltransferases regulates its nuclearâ€"cytoplasmic localization. EMBO Reports, 2006, 7, 727-733.	4.5	55
72	Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell, 2006, 10, 473-486.	16.8	106

#	Article	IF	Citations
73	ATM is Activated by Default in Mitosis, Localizes at Centrosomes and Monitors Mitotic Spindle Integrity. Cell Cycle, 2006, 5, 88-92.	2.6	63
74	Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis. Molecular and Cellular Biology, 2006, 26, 4746-4757.	2.3	93
75	HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene, 2005, 24, 5431-5442.	5.9	63
76	Evaluation of the molecular mechanisms involved in the gain of function of a Li-FraumeniTP53 Mutation. Human Mutation, 2005, 26, 94-103.	2.5	12
77	A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug. Investigational New Drugs, 2005, 23, 195-203.	2.6	16
78	Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization. Cancer Research, 2005, 65, 9687-9694.	0.9	53
79	p53 Localization at Centrosomes during Mitosis and Postmitotic Checkpoint Are ATM-dependent and Require Serine 15 Phosphorylation. Molecular Biology of the Cell, 2004, 15, 3751-3757.	2.1	92
80	5â€Lipoxygenase antagonizes genotoxic stressâ€induced apoptosis by altering p53 nuclear trafficking. FASEB Journal, 2004, 18, 1740-1742.	0.5	40
81	p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death and Differentiation, 2004, 11, 596-607.	11.2	40
82	Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene, 2004, 23, 418-425.	5.9	29
83	HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene, 2004, 23, 5185-5192.	5.9	60
84	Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis. Proteins: Structure, Function and Bioinformatics, 2004, 55, 743-755.	2.6	15
85	Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Experimental Cell Research, 2004, 293, 311-320.	2.6	99
86	TP53INP1s and Homeodomain-interacting Protein Kinase-2 (HIPK2) Are Partners in Regulating p53 Activity. Journal of Biological Chemistry, 2003, 278, 37722-37729.	3.4	140
87	Cloning of the Mouse Insulin Receptor Substrate-3 (mIRS-3) Promoter, and Its Regulation by p53. Molecular Endocrinology, 2002, 16, 1577-1589.	3.7	9
88	Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb. Cancer Cell, 2002, 2, 387-399.	16.8	76
89	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biology, 2002, 4, 11-19.	10.3	636
90	Cloning of the Mouse Insulin Receptor Substrate-3 (mIRS-3) Promoter, and Its Regulation by p53. Molecular Endocrinology, 2002, 16, 1577-1589.	3.7	2

#	Article	IF	Citations
91	From p63 to p53 across p73. FEBS Letters, 2001, 490, 163-170.	2.8	79
92	NF-Y Mediates the Transcriptional Inhibition of thecyclin B1, cyclin B2, and cdc25CPromoters upon Induced G2 Arrest. Journal of Biological Chemistry, 2001, 276, 5570-5576.	3.4	153
93	p53 Displacement from Centrosomes and p53-mediated G1 Arrest following Transient Inhibition of the Mitotic Spindle. Journal of Biological Chemistry, 2001, 276, 19205-19213.	3.4	107
94	Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. Journal of Gene Medicine, 2000, 2, 11-21.	2.8	27
95	p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death and Differentiation, 2000, 7, 506-508.	11.2	31
96	Development of a murine orthotopic model of leukemia: Evaluation of TP53 gene therapy efficacy. Cancer Gene Therapy, 2000, 7, 135-143.	4.6	6
97	Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene, 2000, 19, 3245-3255.	5.9	34
98	P53 Regulates Myogenesis by Triggering the Differentiation Activity of Prb. Journal of Cell Biology, 2000, 151, 1295-1304.	5.2	107
99	Activation of p53 Function in Carcinoma Cells by the Î±6Î²4 Integrin. Journal of Biological Chemistry, 1999, 274, 20733-20737.	3.4	66
100	Growth and Differentiation Signals by the Insulin-like Growth Factor 1 Receptor in Hemopoietic Cells Are Mediated through Different Pathways. Journal of Biological Chemistry, 1999, 274, 12423-12430.	3.4	108
101	P53 Inhibits Î±6Î²4 Integrin Survival Signaling by Promoting the Caspase 3â€“Dependent Cleavage of Akt/PKB. Journal of Cell Biology, 1999, 147, 1063-1072.	5.2	171
102	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Therapy, 1999, 6, 1064-1072.	4.5	31
103	The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. Oncogene, 1999, 18, 5831-5835.	5.9	27
104	Evaluating virus-transformed cell tumorigenicity. Journal of Virological Methods, 1999, 79, 41-50.	2.1	12
105	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. British Journal of Cancer, 1998, 78, 1541-1546.	6.4	11
106	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity. , 1998, 16, 117-122.		3
107	Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. British Journal of Cancer, 1998, 77, 1429-1438.	6.4	29
108	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood, 1998, 91, 4342-4349.	1.4	112

#	Article	IF	Citations
109	Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. Gene Therapy, 1997, 4, 1371-1378.	4.5	21
110	p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene, 1997, 14, 729-740.	5.9	141
111	Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. Oncogene, 1997, 15, 607-611.	5.9	5
112	The Î²4Integrin Subunit Is Expressed in Mouse Fibroblasts and Modulated by Transforming Growth Factor-Î²1. Experimental Cell Research, 1996, 227, 223-229.	2.6	10
113	Interference with p53 protein inhibits hematopoietic and muscle differentiation.. Journal of Cell Biology, 1996, 134, 193-204.	5.2	118
114	Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.. Journal of Clinical Investigation, 1996, 98, 1165-1173.	8.2	47
115	Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. Journal of Cellular Physiology, 1995, 162, 26-35.	4.1	61
116	Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells. European Journal of Cancer, 1995, 31, 447-452.	2.8	16
117	The effects of end point overdispersions on the validity of single-dose tumorigenicity assays. Cancer Letters, 1995, 93, 179-186.	7.2	3
118	Adenovirus Infection Induces Reentry into the Cell Cycle of Terminally Differentiated Skeletal Muscle Cells. Annals of the New York Academy of Sciences, 1995, 752, 9-18.	3.8	17
119	Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants. Clinical and Experimental Metastasis, 1993, 11, 368-376.	3.3	11
120	Studies on Cell-mediated Immune Defects to Epstein-Barr Virus and Cytomegalovirus in HIV-related Disorders. Annals of the New York Academy of Sciences, 1987, 511, 385-389.	3.8	1
121	Immune response to cytomegalovirus in patients with acquired-immunodeficiency syndrome related complex (ARC) and AIDS. European Journal of Epidemiology, 1987, 3, 439-441.	5.7	2